We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLIN
RNS Number : 9516N
Clinigen Group plc
04 October 2021
4 October 2021
Grant of share options and PDMR notification
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 1 October 2021, the following Directors were granted share options over a total of 118,110 ordinary shares of
0.1 pence each ("Ordinary Shares"), granted under the Clinigen Group Long Term Incentive Plan 2015. The options are nil cost options intended to vest on 1 October 2024 subject to the achievement of certain performance criteria.
Director/PDMR Number of Total number Total number Total number share options of share of ordinary of ordinary granted options now shares now shares (excluding held held share options) as % issued share capital Shaun Chilton 118,110 732,074 330,044 0.25% --------------- ------------- ------------- -------------------
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated a) Name Shaun Chilton --------------------------- ------------------------------------- 2 Reason for the notification ------------------------------------------------------------------ a) Position/status Group Chief Executive Officer --------------------------- ------------------------------------- b) Initial notification Initial Notification /Amendment --------------------------- ------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------ a) Name Clinigen Group plc --------------------------- ------------------------------------- b) Legal Entity 213800OBIKGI2JYYS227 Identifier --------------------------- ------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description Ordinary shares of 0.1 pence each of the financial GB00B89J2419 instrument, type of instrument Identification code --------------------------- ------------------------------------- b) Nature of the Grant of Options transaction --------------------------- ------------------------------------- c) Currency GBP --------------------------- ------------------------------------- d) Price(s) and Price(s) Volume(s) volume(s) --------------------------- ------------------ ----------------- Nil 118,110 --------------------------------------------------- ----------------- e) Aggregated 118,110 information Nil - Aggregated volume - Price - Aggregated total --------------------------- ------------------------------------- f) Date of the 1 October 2021 transaction --------------------------- ------------------------------------- g) Place of the London Stock Exchange, AIM transaction --------------------------- -------------------------------------
-Ends-
For more information, please contact:
Clinigen Group plc +44 (0) 1283 495010 Shaun Chilton, Chief Executive Officer investors@clinigengroup.com Rob Fox, VP Investor Relations and Corporate Development Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260 & Joint Broker 1000 James Black / Garry Levin / Freddie Barnfield c linigen@Numis.com RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653 4000 Marcus Jackson / Elliot Thomas Consilium Strategic Communications Mary-Jane Elliott / Matthew Cole / Jessica Tel: +44 (0) 20 3709 Hodgson 5700 c linigen@consilium-comms.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products company focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 120 countries.
For more information on Clinigen, please visit http://www.clinigen.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFLFISIRLSIIL
(END) Dow Jones Newswires
October 04, 2021 10:10 ET (14:10 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions